Log in

Relevant bibliographies by topics / Genetically engineered drugs

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Genetically engineered drugs'

Author: Grafiati

Published: 27 May 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Genetically engineered drugs.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Genetically engineered drugs"

1

Jones-Grizzle, Amy J., and J. Lyle Bootman. "Pharmacoeconomics of Genetically Engineered Drugs." PharmacoEconomics 1, no. 1 (1992): 45–53. http://dx.doi.org/10.2165/00019053-199201010-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kishore, Kamal, and Pawan Krishan. "Pharmacology of recombinant or genetically engineered drugs." Journal of Young Pharmacists 1, no. 2 (2009): 141. http://dx.doi.org/10.4103/0975-1483.55747.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Khobeysh, M. M., and E. V. Sokolovskiy. "Genetically engineered biologics to treat psoriasis. Experience with ustekinumab in an adolescent with severe psoriasis." Meditsinskiy sovet = Medical Council, no. 1 (March 12, 2023): 123–29. http://dx.doi.org/10.21518/ms2023-003.

Full text

Abstract:

Modern pathogenetic therapy of psoriasis is the use of suppressive methods aimed to suppress immune reactions in the dermis, synovia, enthesis and eliminate the imbalance between anti-inflammatory and pro-inflammatory cytokines, chemokines. Today, genetically engineered biological drugs are one of the most promising pharmacotherapy achievements for the management of psoriasis, psoriatic arthritis in the group of immunosuppressive agents. Knowing the pathogenetic mechanisms that underlie the development of these diseases allows us today to highly selectively target the top key links of the immu

APA, Harvard, Vancouver, ISO, and other styles

4

Матюнова, Алла, Alla Matyunova, Людмила Брегель, and Lyudmila Bregel. "MODERN JUVENILE IDIOPATHIC ARTHRITIS THERAPY OF WITH THE USE OF BIOLOGICAL MEDICATIONS IN A REGIONAL CHILDREN”S 3 LEVEL HOSPITAL - RESULTS AND PROBLEMS." Acta biomedica scientifica 2, no. 5 (2018): 102–6. http://dx.doi.org/10.12737/article_5a3a0e4744a0a8.88140750.

Full text

Abstract:

Background. Juvenile idiopathic arthritis is accompanied by severe functional disabilities refractory to standard treat- ment with methotrexate. Recently introduced genetic engineering has significantly improved the functional state of the patients with persistent disease and stopped the progressive destruction of joints. However, the risk of adverse reactions against the background of this type of therapy requires further study. Aims: to analyze the efficiency of the genetically engineered drugs applied at juvenile arthritis and undesirable effects of this treatm

APA, Harvard, Vancouver, ISO, and other styles

5

Huang, Ya Qiong, Kenneth L. White, De Shun Shi, et al. "Development and Prospect of Genetically Engineered Pharmaceutics." Advanced Materials Research 746 (August 2013): 588–92. http://dx.doi.org/10.4028/www.scientific.net/amr.746.588.

Full text

Abstract:

With the rapid development of modern biology and technology, Genetically Engineered Pharmaceutics has become the most important field in modern medicinal industry. Currently, we have taken concern that the Genetically Engineered Pharmaceutics has been a subject of research. As advanced genetically engineered technology, genetic therapy, the point mutation techniques, DNA shuffling, RNA interference (RNAi) technology, the bioinformatics for genome and proteome analyses, the high throughput screening technology, etc. can be applied in the treatment of cancer, and other targeted therapies. A grea

APA, Harvard, Vancouver, ISO, and other styles

6

Zyryanov, S. K., and O. I. Butranova. "Genetically engineered drugs for treatment of bronchial asthma: recent achievements." Russian Pulmonology 28, no. 5 (2018): 584–601. http://dx.doi.org/10.18093/0869-0189-2018-28-5-584-601.

Full text

Abstract:

Current population of patients with asthma is characterized by increasing resistance to standard pharmacotherapeutic agents such as inhaled corticosteroids, antileukotriene agents and anti-IgE antibodies. These findings were confirmed by international statistic data and indicate insufficient efficacy of the treatment. Asthma phenotyping encompassing a role of certain biomarkers for bronchial inflammation could contribute to achieving better response to treatment. Genetically engineered drugs could directly impact on mediators and modulators involved in the inflammation and bronchoconstriction.

APA, Harvard, Vancouver, ISO, and other styles

7

Leonova, K. "Selected problems in the use of genetic engineering biological therapy in patients with rheumatoid arthritis." Clinical Medicine and Pharmacology 6, no. 4 (2021): 36–39. http://dx.doi.org/10.12737/2409-3750-2021-6-4-36-39.

Full text

Abstract:

Rheumatoid arthritis, like any chronic non-infectious disease, requires constant pharmacological therapy and monitoring of treatment. To relieve exacerbation, maintain long-term remission and improve the quality of life of patients, basic anti-inflammatory drugs are used, which have passed many years of testing for efficacy and safety and are available for patients. But there is a group of drugs that have appeared relatively recently - genetically engineered biological drugs. At the moment, their use is somewhat limited due to the presence of a number of problems. With the accumulation of data

APA, Harvard, Vancouver, ISO, and other styles

8

Avdeev, Sergey N., Alexandr V. Emelyanov, Oksana M. Kurbacheva, et al. "A new delivery device for benralizumab (autoinjector, pen-injector device) in the clinical practice of treating severe eosinophilic asthma: Conclusion of the Expert Council." PULMONOLOGIYA 31, no. 6 (2021): 776–81. http://dx.doi.org/10.18093/0869-0189-2021-31-6-776-781.

Full text

Abstract:

The emergence of new means of administering genetically-engineered biological drugs, such as an autoinjector (pen injector device), can positively affect the organizational aspects of treating patients with severe eosinophilic asthma (SA) who need biological therapy.The aim. To determine the place of a new delivery device for benralizumab (autoinjector, pen injector device) in the clinical practice of treating eosinophilic SA.Results. The expert council considered the results of the latest clinical studies and real practice data on the use of genetically-engineered biological drugs in the form

APA, Harvard, Vancouver, ISO, and other styles

9

Cho, Kyungjoo, Simon Weonsang Ro, Sang Hyun Seo, et al. "Genetically Engineered Mouse Models for Liver Cancer." Cancers 12, no. 1 (2019): 14. http://dx.doi.org/10.3390/cancers12010014.

Full text

Abstract:

Liver cancer is the fourth leading cause of cancer-related death globally, accounting for approximately 800,000 deaths annually. Hepatocellular carcinoma (HCC) is the most common type of liver cancer, comprising approximately 80% of cases. Murine models of HCC, such as chemically-induced models, xenograft models, and genetically engineered mouse (GEM) models, are valuable tools to reproduce human HCC biopathology and biochemistry. These models can be used to identify potential biomarkers, evaluate potential novel therapeutic drugs in pre-clinical trials, and develop molecular target therapies.

APA, Harvard, Vancouver, ISO, and other styles

10

Samigullina, R. R., V. I. Mazurov, and E. A. Trofimov. "Characteristics of complex therapy of immuno-inflammatory rheumatic diseases in COVID-19 pandemic conditions." Russian Medical Inquiry 5, no. 5 (2021): 260–67. http://dx.doi.org/10.32364/2587-6821-2021-5-5-260-267.

Full text

Abstract:

The rapid spread of a new coronavirus infection (COVID-19) requires innovative solutions, including tactics optimization in using genetically engineered and targeted drugs in patients with immuno-inflammatory rheumatic diseases (RD). The authors studied the characteristics of the complex therapy of immuno-inflammatory RD in the COVID-19 pandemic conditions, analyzed the COVID-19 course in patients with RD who received combined therapy with genetically engineered and basic synthetic anti-rheumatic drugs and were under follow-up from March 2020 to March 2021. The researchers found that synthetic

APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Genetically engineered drugs"

1

Mustafa, Suhad As'ad. "The development of genetically engineered bacterial enzymes as sensor biological recognition elements for the detection of drugs and explosives." Thesis, Bangor University, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.540409.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Creedon, Helen. "Use of genetically engineered mouse models in preclinical drug development." Thesis, University of Edinburgh, 2015. http://hdl.handle.net/1842/15911.

Full text

Abstract:

The paucity of well validated preclinical models is frequently cited as a contributing factor to the high attrition rates seen in clinical oncological trials. There remains a critical need to develop models which are accurately able to recapitulate the features of human disease. The aims of this study were to use genetically engineered mouse models (GEMMs) to explore the efficacy of novel treatment strategies in HER2 positive breast cancer and to further develop the model to facilitate the study of mechanisms underpinning drug resistance. Using the BLG--HER2KI-PTEN+/- model, we demonstrated th

APA, Harvard, Vancouver, ISO, and other styles

3

Gning, Fatima. "Construction d’une usine pharmaceutique : impératifs réglementaires, sécuritaires et de rentabilité." Electronic Thesis or Diss., Université Paris-Panthéon-Assas, 2022. http://www.theses.fr/2022ASSA0078.

Full text

Abstract:

L’industrie pharmaceutique est continuellement confrontée à d’importantes mutations qui redéfinissent sans cesse l’équilibre entre la protection de la santé publique et les stratégies de développement économique des sociétés pharmaceutiques. Le marché du médicament est le terrain de forts enjeux économiques pour la France et l’accroissement de ses parts de marché mondial reste une préoccupation majeure. L’atteinte de cet objectif semble se faire autour d’un premier axe ayant trait au développement du génie génétique. Le second axe concerne la construction de nouvelles usines de production à l’

APA, Harvard, Vancouver, ISO, and other styles

4

Jung, Lin Wan, and 林婉蓉. "Safety and Quality Regulation of Biomedicine in Taiwan and China: Focus on Genetically Engineered Drug." Thesis, 2015. http://ndltd.ncl.edu.tw/handle/24410564380688915598.

Full text

Abstract:

碩士<br>國立清華大學<br>科技法律研究所<br>103<br>As the problems of safety and drug tolerance of chemicals get ever more serious, the market of biomedicine grows rapidly to make up for the deficiencies of chemicals in remedial areas. Regulations in Taiwan and China and applications thereof which shall be followed through different stages when promoting genetic engineered medicine into market are discussed in this thesis. Since genetic engineered medicine is categorized as one sort of biomedicine, it should be in accordance with the rules set for biomedicine first and be further considered if regulations targ

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Genetically engineered drugs"

1

Copsey, David N., and Sabine Y. J. Delnatte. Genetically Engineered Human Therapeutic Drugs. Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09800-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

N, Copsey David, and Delnatte Sabine Y. J, eds. Genetically engineered human therapeutic drugs. Stockton Press, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Dictionary of Genetically Engineered Human Therapeutic Drugs. Pan Macmillan, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

GOVERNMENT, US. 21st Century Complete Guide to Biotechnology: Federal Research and Regulation, Bioengineered and Genetically Modified (GM) Crops, Seeds, Foods, and Drugs, Genetically Engineered Organisms, Agricultural Biotechnology (DVD-ROM). Progressive Management, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

US GOVERNMENT. 2005 Biotechnology Encyclopedia: Federal Research and Regulation, Bioengineered and Genetically Modified (GM) Crops, Seeds, Foods, and Drugs, Genetically Engineered (GE) Organisms, Agricultural Biotechnology, FDA, USDA, EPA, NIH, DOE (DVD-ROM). Progressive Management, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

US GOVERNMENT. 21st Century Essential Guide to Genetic Engineering and Biotechnology: Federal Research and Regulation, Bioengineered and Genetically Modified (GM) Crops, Seeds, Foods, and Drugs, Genetically Engineered (GE) Organisms, Agricultural Biotechnology, FDA, USDA, EPA, NIH, DOE (DVD-ROM). Progressive Management, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Bates, Gillian P., and Christian Landles. Preclinical Experimental Therapeutics. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199929146.003.0016.

Full text

Abstract:

This chapter begins by reviewing the mammalian models of Huntington’s disease (HD) that have been developed using mice, rats, and a number of large animals, including sheep, pigs, and nonhuman primates. Analysis of these models, together with genetically engineered mice created through specific manipulations of the mouse genome, has provided considerable insights into the molecular pathogenesis of HD. The number of potential therapeutic targets that have been proposed for HD is considerable, and their preclinical evaluation in HD mouse models is being used to select targets that should be purs

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Genetically engineered drugs"

1

Hentschel, Christopher. "Overview: Recombinant DNA Proteins and Drug Discovery." In Genetically Engineered Human Therapeutic Drugs. Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09800-2_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Balkwill, Frances R. "Cytokines in Cancer Therapy." In Genetically Engineered Human Therapeutic Drugs. Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09800-2_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Duff, Gordon W., Julian A. Symons, and Francesco S. Di Giovine. "Recombinant DNA Proteins and Prospects for Treatment of Inflammatory Diseases." In Genetically Engineered Human Therapeutic Drugs. Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09800-2_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Tuddenham, Edward. "Cardiovascular and Blood-Related Proteins." In Genetically Engineered Human Therapeutic Drugs. Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09800-2_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Gordon, Sarah L. "Overview of Commercial Prospects for Biotechnology Products in Health Care." In Genetically Engineered Human Therapeutic Drugs. Macmillan Education UK, 1988. http://dx.doi.org/10.1007/978-1-349-09800-2_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Gillies, Stephen D. "Designing immunocytokines: genetically engineered fusion proteins for targeted immune therapy." In Recombinant Protein Drugs. Birkhäuser Basel, 2001. http://dx.doi.org/10.1007/978-3-0348-8346-7_6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Sacca, Rosalba, Sandra J. Engle, Wenning Qin, Jeffrey L. Stock, and John D. McNeish. "Genetically Engineered Mouse Models in Drug Discovery Research." In Methods in Molecular Biology. Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60761-058-8_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Carbajal, Eletha, and Eric C. Holland. "Mouse Models in Preclinical Drug Development: Applications to CNS Models." In Genetically Engineered Mice for Cancer Research. Springer New York, 2011. http://dx.doi.org/10.1007/978-0-387-69805-2_26.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Loeber, Gerhard, and Renate Schnitzer. "The use of Genetically Engineered Cells in Drug Discovery." In Genetic Engineering. Springer US, 1998. http://dx.doi.org/10.1007/978-1-4899-1739-3_13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Floyd, Warren, Hsuan-Cheng Kuo, Jonathon E. Himes, Rutulkumar Patel, and David G. Kirsch. "Genetically Engineered Mouse Models for Studying Radiation Biology and Radiosensitizers." In Cancer Drug Discovery and Development. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-49701-9_8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Genetically engineered drugs"

1

Aksenova, Valentina, Nadezda Klevno, Elena Dementjeva, and Alexey Kazakov. "TB infection in children receiving genetically engineered biologic drugs." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa3626.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Toner, Mehmet. "Moving Living Cells and Fluids on Microchips for Diagnostics." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-192786.

Full text

Abstract:

Biomedical applications of microfabricated devices is no longer limited to non-living systems as genes-on-a-chip or lab-on-a-chip, recent advances in the understanding of cellular behavior in microenvironments have started to pave the way toward living micro-devices. These emerging devices are expected to become key technologies in the 21st century of medicine with a broad range of applications varying from diagnostic, tissue engineered products, cell-based drug screening tools, and basic molecular biology tools. They will also include multiple cell types and/or genetically engineered cells to

APA, Harvard, Vancouver, ISO, and other styles

3

Silva, Maísa de Carvalho, Lariza Laura De Oliveira, and Renato Tinós. "Optimization of Expanded Genetic Codes via Genetic Algorithms." In XV Encontro Nacional de Inteligência Artificial e Computacional. Sociedade Brasileira de Computação - SBC, 2018. http://dx.doi.org/10.5753/eniac.2018.4440.

Full text

Abstract:

In the last decades, researchers have proposed the use of genetically modified organisms that utilize unnatural amino acids, i.e., amino acids other than the 20 amino acids encoded in the standard genetic code. Unnatural amino acids have been incorporated into genetically engineered organisms for the development of new drugs, fuels and chemicals. When new amino acids are incorporated, it is necessary to modify the standard genetic code. Expanded genetic codes have been created without considering the robustness of the code. The objective of this work is the use of genetic algorithms (GAs) for

APA, Harvard, Vancouver, ISO, and other styles

4

Sharpless, Norman E. "Abstract CN03-01: Drug testing in genetically engineered murine models." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-cn03-01.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Qiu, Weiguo, Joseph Cappello, and Xiaoyi Wu. "Fabrication of Genetically Engineered Silk-Elastin-Like Protein Polymer Fibers." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-190980.

Full text

Abstract:

Micro- and submicro-diameter protein fibers are fundamental building blocks of extra- and intra-cellular matrices, providing structural support, stability and protection to cells, tissues and organism [1]. Fabricating performance fibers of both naturally derived and genetically engineered proteins has been extensively pursued for a variety of biomedical applications, including tissue engineering and drug delivery [2]. Silk-elastin-like proteins (SELPs), consisting of tandemly repeated polypeptide sequences derived from silk and elastin, have been biosynthesized using recombinant DNA technique

APA, Harvard, Vancouver, ISO, and other styles

6

Teng, Weibing, Joseph Cappello, and Xiaoyi Wu. "Viscoelastic Properties of Genetically Engineered Silk-Elastin-Like Protein Polymers." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-192252.

Full text

Abstract:

Genetic engineering of protein-based materials provides material scientists with high levels of control in material microstructures, properties, and functions [1]. For example, multi-block protein copolymers in which individual block may possess distinct mechanical or biological properties have been biosynthesized [2, 3]. Polypeptide sequences derived from well-studied structural proteins (e.g., collagen, silk, elastin) are often used as motifs in the design and synthesis of new protein-based material, in which new functional groups may be incorporated. In this fashion, we have produced a seri

APA, Harvard, Vancouver, ISO, and other styles

7

Lowe, Scott W. "Abstract PL01-03: Drug resistance and tumor maintenance in genetically engineered mice." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/1535-7163.targ-09-pl01-03.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Seidel, Diana, Anastasia Shibina, C. Patrick Reynolds, Winfried S. Wels, Nicole Huebener, and Holger N. Lode. "Abstract 2808: GD2-specific genetically engineered NK cell therapy is effective in a drug-resistant neuroblastoma xenograft mouse model." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-2808.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Lee, Edmund Chun Yu, Michael Fitzgerald, Bret Bannerman, et al. "Abstract 397: The antitumor activity of the investigational drug MLN9708 in genetically engineered mouse models of plasma cell malignancy." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-397.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Cuppoletti, John. "Composite Synthetic Membranes Containing Native and Engineered Transport Proteins." In ASME 2008 Conference on Smart Materials, Adaptive Structures and Intelligent Systems. ASMEDC, 2008. http://dx.doi.org/10.1115/smasis2008-449.

Full text

Abstract:

Our membrane transport protein laboratory has worked with material scientists, computational chemists and electrical and mechanical engineers to design bioactuators and sensing devices. The group has demonstrated that it is possible to produce materials composed native and engineered biological transport proteins in a variety of synthetic porous and solid materials. Biological transport proteins found in nature include pumps, which use energy to produce gradients of solutes, ion channels, which dissipate ion gradients, and a variety of carriers which can either transport substances down gradie

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!